Patent ID: 8007827
Filing Date: 2011-08-30
Classification: A61K

Abstract:
1. A pharmaceutical dosage form of an absorption window active agent selected from the group consisting of baclofen, gabapentin, levodopa, α-methyldopa, valacyclovir, or a mixture of any thereof that exhibits prolonged absorption of the active agent in the small intestine comprising a plurality of controlled release particles, each particle comprising: i. the absorption window active agent selected from the group consisting of baclofen, gabapentin, levodopa, α-methyldopa, valacyclovir, or a mixture of any thereof; ii. an inner pH-sensitive polymer layer substantially enveloping the absorption window active agent; and iii. an outer pH-sensitive polymer layer substantially enveloping the absorption window active agent and inner pH-sensitive layer; wherein the dosage form provides prolonged absorption of the absorption window active agent in the small intestine, and wherein the outer pH-sensitive polymer layer dissolves at a lower pH than the inner pH-sensitive polymer layer.